X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net proceeds will be used to advance the commercialization of APHEXDA (motixafortide) approved with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma.
Lead Product(s): Motixafortide,Filgrastim
Therapeutic Area: Oncology Product Name: Aphexda
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: BlackRock
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 10, 2024
Details:
BioLineRx intends to use the proceeds to support the commercialization of APHEXDA (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in patients with multiple myeloma.
Lead Product(s): Motixafortide,Filgrastim
Therapeutic Area: Oncology Product Name: Aphexda
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: JonesTrading Institutional Services
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 01, 2024
Details:
BL-8040 (motixafortide) is a CXCR4 inhibitor, which is being evaluated in combination with cemiplimab, and standard of care chemotherapies for the treatment of Pancreatic ductal adenocarcinoma.
Lead Product(s): Motixafortide,Cemiplimab,Gemcitabine
Therapeutic Area: Oncology Product Name: BL-8040
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
BioLineRx initiated Phase I clinical trial studies evaluating BL-8040 (motixafortide), CXCR4/SDF-1 inhibitor, as monotherapy and in combination with natalizumab for the treatment of sickle cell disease.
Lead Product(s): Motixafortide,Natalizumab
Therapeutic Area: Hematology Product Name: BL-8040
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
Under the agreement, BioLineRx gain the rights for the development of Aphexda (motixafortide), a CXCR4 antagonist, in stem cell mobilization and pancreatic cancer, in Asia.
Lead Product(s): Motixafortide,G-CSF
Therapeutic Area: Oncology Product Name: Aphexda
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Gloria Biosciences
Deal Size: $279.6 million Upfront Cash: $29.6 million
Deal Type: Licensing Agreement October 31, 2023
Details:
Aphexda (motixafortide) is a CXCR4 antagonist , which is investigated in combination with gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancers.
Lead Product(s): Motixafortide,Natalizumab
Therapeutic Area: Oncology Product Name: Aphexda
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
APHEXDA (motixafortide) is a CXCR4 antagonist , which is investigated in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.
Lead Product(s): Motixafortide,G-CSF
Therapeutic Area: Oncology Product Name: Aphexda
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
BL-8040 (motixafortide) inhibits CXCR4, a chemokine receptor and a well validated therapeutic target that is over-expressed in many human cancers including pancreatic ductal adenocarcinoma (PDAC).
Lead Product(s): Motixafortide,Natalizumab
Therapeutic Area: Oncology Product Name: BL-8040
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
The aim of the collaboration is to advance a Phase 1 clinical trial that will evaluate the safety and feasibility of BL-8040 (motixafortide) to mobilize CD34+ hematopoietic stem cells (HSCs) for gene therapies in sickle cell disease (SCD).
Lead Product(s): Motixafortide,Natalizumab
Therapeutic Area: Genetic Disease Product Name: BL-8040
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Washington University School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 06, 2023
Details:
APHEXDA® (motixafortide) in stem cell mobilization for autologous transplantation in multiple myeloma patients. APHEXDA has the potential to significantly improve outcomes and treatment experiences for patients with multiple myeloma.
Lead Product(s): Motixafortide,G-CSF
Therapeutic Area: Oncology Product Name: Aphexda
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
Motixafortide (aphexda) is a novel selective inhibitor of the CXCR4 chemokine receptor. Motixafortide’s unique features including high-affinity, long receptor occupancy and inverse agonist activity position it as the best-in-class antagonist of CXCR4.
Lead Product(s): Motixafortide,G-CSF
Therapeutic Area: Oncology Product Name: Aphexda
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Details:
Under the terms of the agreement, GenFleet will fully fund, design and execute a randomized Phase 2b clinical trial for BL-8040 (motixafortide) that will enroll approximately 200 first-line metastatic PDAC patients in China.
Lead Product(s): Motixafortide,Pembrolizumab,Calcium Folinate
Therapeutic Area: Oncology Product Name: BL-8040
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: GenFleet Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 28, 2022
Details:
Results demonstrate highly significant cost benefits of using Motixafortide in combination with G-CSF, versus plerixafor with G-CSF, for stem cell mobilization in all multiple myeloma patients undergoing autologous stem cell transplantation.
Lead Product(s): Motixafortide,G-CSF
Therapeutic Area: Oncology Product Name: BL-8040
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2022
Details:
The study concluded that the addition of Motixafortide to G-CSF (the current standard of care) is associated with a statistically significant decrease in health resource utilization (HRU) during the ASCT process, compared to G-CSF alone.
Lead Product(s): Motixafortide,G-CSF
Therapeutic Area: Oncology Product Name: BL-8040
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
Details:
The results of the study showed substantial improvement as compared to historical results across all study endpoints. BioLineRx plans to present the full data set at an upcoming medical conference.
Lead Product(s): Motixafortide,Pembrolizumab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: BL-8040
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2020
Details:
The Company's lead program, motixafortide (BL-8040), is a cancer therapy platform currently being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a collaboration agreement with MSD.
Lead Product(s): Motixafortide,G-CSF
Therapeutic Area: Oncology Product Name: BL-8040
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2020
Details:
Company's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be tested in combination with the anti-PD-1 cemiplimab (LIBTAYO®) and standard-of-care chemotherapy (gemcitabine and nab-paclitaxel) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC).
Lead Product(s): Motixafortide,Cemiplimab,Gemcitabine
Therapeutic Area: Oncology Product Name: BL-8040
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
This ongoing registrational study is investigating motixafortide (BL-8040) for the mobilization of hematopoietic stem cells (HSCs) for autologous transplantation in patients with multiple myeloma.
Lead Product(s): Motixafortide,G-CSF
Therapeutic Area: Oncology Product Name: BL-8040
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Details:
The paper highlights previously disclosed biomarker and data from the Company's ongoing COMBAT/KEYNOTE-202 clinical trial, consisting of two cohorts assessing the safety, efficacy and immunobiological effects in patients with metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Motixafortide,Pembrolizumab,Fluorouracil
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
Details:
The patent will be valid until July 2036 with a possibility of up to five years patent term extension.
Lead Product(s): Motixafortide,Pembrolizumab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
Details:
Patients receive Motixafortide monotherapy priming treatment for five days, followed by combination cycles of chemotherapy, KEYTRUDA® and Motixafortide until progression.
Lead Product(s): Motixafortide,Pembrolizumab,Fluorouracil
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2020
Details:
Motixafortide is currently being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a collaboration agreement with Merck.
Lead Product(s): Motixafortide,Pembrolizumab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
